(PFS), and overall survival (OS). In cohort 1, multiple time points were performed up to progression. Additionally MMP2 and MMP9 plasma levels were analyzed in patients with newly diagnosed GB, after surgery. Finally, MMP2 and 9 RNA were assessed in tumor tissue of a separated group of paired newly diagnosed and recurrent GB (n ¼ 29). RESULTS: In cohort1, high MMP2 baseline level was associated to a probability of OR of 83.3% versus 15.4% in case of low MMP2 level (p ¼ 0.001). In multivariate analysis, baseline level of MMP2 correlated with PFS (hazard-ratio(HR), 3.92; 95% confidence-interval(CI):1.46-10.52; p ¼ 0.007) and OS (HR, 4.62; 95%CI 1.58-13.53; p ¼ 0.005), as decrease of VEGF (p ¼ 0.038 for PFS and p ¼ 0.013 for OS) and MMP9 (p ¼ 0.016 for PFS and p¼ 0.025 for OS). In cohort2, MMP2, but not MMP9, confirmed its predictive significance. In cohort3, no association was found between MMP2, MMP9 and outcome. In cohort 1, significant changes in MMP2 and MMP9 plasma levels were observed during treatment. MMP2 increased after Bev initiation (p ¼ 0.002), and decreased at progression (p ¼ 0.002) while MMP9 initially decreased (p ¼ 0.007) then increased at progression (p ¼ 0.031). No significant difference was observed both for plasma level and tissue RNA expression between newly diagnosed and recurrent GB. CONCLUSIONS: In patients with recurrent HGG treated with bevacizumab, but not with cytotoxic agent, high MMP2 plasma levels are associated with prolonged tumor control and survival, while changes over time may reflect tumor control. Comparison of MMP2/MMP9 levels between initial diagnosis and recurrence may suggest that bevacizumab could be similarly effective in this two setting. MMP2 should be tested in randomized clinical trials that evaluate bevacizumab efficacy, and its biological role reassessed. SECONDARY CATEGORY: Clinical Neuro-Oncology. -Oncology 16:iii42 -iii52, 2014 -Oncology 16:iii42 -iii52, . doi:10.1093 
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